EUROPEAN FORUM ON ANTIPHOSPHOLIPID ANTIBODIES

MULTICENTRE STUDIES

WARFARIN IN THE ANTIPHOSPHOLIPID SYNDROME (WASP)

Prospective randomized clinical trial to assess the risk/benefit ratio of high dose (INR>3) oral anticoagulation in patients with the Antiphospholipid Syndrome.

Organized in the frame of the SSC Subcommittee on Lupus Anticoagulant and Antiphospholipid Antibodies of the International Society of Thrombosis and Haemostasis (ISTH) and coordinated by Guido Finazzi and Douglas Triplett.

For additional information and applications, please e-mail: Dr. Guido Finazzi at e-mail: ematologia@cyberg.it